Home > Boards > US Listed > Biotechs > DermTech Inc (DMTK)

DermTech to Present at Upcoming Investor Conferences

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
db7 Member Profile
Member Level 
Followed By 206
Posts 39,187
Boards Moderated 0
Alias Born 09/02/03
160x600 placeholder
DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Lar... Business Wire - 1/14/2021 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/13/2021 4:22:13 PM
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cuta... Business Wire - 1/12/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/11/2021 6:05:37 PM
DermTech Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purchase Additiona... Business Wire - 1/11/2021 4:01:00 PM
DermTech Announces Pricing of Public Offering of Common Stock Business Wire - 1/7/2021
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2021 4:11:03 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/6/2021 4:07:36 PM
DermTech Announces Proposed Public Offering of Common Stock Business Wire - 1/6/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/5/2021 5:26:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 1/5/2021 4:37:54 PM
DermTech Announces Appointment of General Counsel Business Wire - 1/5/2021 4:30:00 PM
DermTech Receives Positive Medical Coverage by Geisinger Health System Business Wire - 12/29/2020 5:05:00 PM
DermTech Management to Present at the ICR Conference 2021 Business Wire - 12/28/2020 4:01:00 PM
DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% &... Business Wire - 12/17/2020 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2020 4:40:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/16/2020 4:37:46 PM
DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Gr... Business Wire - 12/11/2020 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2020 6:05:25 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:11:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:08:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2020 4:07:34 PM
DermTech Enters Into Agreement With Blue Shield of California Business Wire - 12/10/2020 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/9/2020 4:44:40 PM
DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit Business Wire - 12/3/2020 4:30:00 PM
db7 Member Level  Tuesday, 02/11/20 05:51:20 PM
Re: None
Post # of 95 
DermTech to Present at Upcoming Investor Conferences

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that John Dobak, M.D., Chief Executive Officer of the Company, is scheduled to present at the following upcoming investor conferences:
• The 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 2:30 p.m. Eastern Time at the Lotte New York Palace hotel in New York.
• Cowen’s 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. Eastern Time at the Boston Marriott Copley Place hotel in Boston.

About DermTech:

DermTech is a leader in a new category of medicine, precision dermatology. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to the performance, patient benefits and cost-effectiveness of DermTech’s products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) by the company, and (y) other documents filed or to be filed with the SEC by the company. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.



View source version on businesswire.com: https://www.businesswire.com/news/home/20200211006081/en/

Company Contact:
Sarah Dion
VP Marketing
sdion@dermtech.com
(858) 450-4222

Investors:
Westwicke, an ICR company
Caroline Corner, PhD
caroline.corner@westwicke.com
(415) 202-5678



-------------------------------------------------------------------

All posts are strictly my opinion and are not buy or sell recommendations.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences